



Final Appraisal Recommendation
Advice No: 1221 – September 2021

Amikacin liposomal (Arikayce®) 590 mg nebuliser dispersion

Submission by Insmmed Ltd

Recommendation of AWMSG

Amikacin liposomal (Arikayce®) is recommended as an option for use within NHS Wales for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by *Mycobacterium avium* Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered amikacin liposomal (Arikayce®) as an ultra-orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2140), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1221:
Amikacin liposomal (Arikayce®) 590 mg nebuliser dispersion. September 2021